0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Narrative Review: Ketosis-Prone Type 2 Diabetes Mellitus

Guillermo E. Umpierrez, MD; Dawn Smiley, MD; and Abbas E. Kitabchi, PhD, MD
[+] Article and Author Information

From Emory University School of Medicine, Atlanta, Georgia, and University of Tennessee Health Science Center, Memphis, Tennessee.


Grant Support: In part by research grants from the American Diabetes Association (7-03-CR-35) (Dr. Umpierrez) and National Institutes of Health (R03 DK073190-01 and MO1-RR00039 [Dr. Umpierrez] and RR00211 [Drs. Kitabchi and Umpierrez]).

Potential Financial Conflicts of Interest: Grants received: A.E. Kitabchi (Lilly, Novo, Takeda, Aventis, Abbott).

Requests for Single Reprints: Guillermo E. Umpierrez, MD, Emory University School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303; e-mail, geumpie@emory.edu.

Current Author Addresses: Drs. Umpierrez and Smiley: Emory University School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303.

Dr. Kitabchi: University of Tennessee Health Science Center, Room 334D, 956 Court Avenue, Memphis, TN 38163.


Ann Intern Med. 2006;144(5):350-357. doi:10.7326/0003-4819-144-5-200603070-00011
Text Size: A A A

Several investigators have reported that more than half of African-American persons with new diagnoses of diabetic ketoacidosis have clinical, metabolic, and immunologic features of type 2 diabetes during follow-up. These patients are usually obese, have a strong family history of diabetes, have a low prevalence of autoimmune markers, and lack a genetic association with HLA. Their initial presentation is acute, with a few days to weeks of polyuria, polydipsia, and weight loss and lack of a precipitating cause of metabolic decompensation. At presentation, they have markedly impaired insulin secretion and insulin action, but intensified diabetic management results in significant improvement in β-cell function and insulin sensitivity sufficient to allow discontinuation of insulin therapy within a few months of follow-up. On discontinuation of insulin therapy, the period of near-normoglycemic remission may last for a few months to several years. The absence of autoimmune markers and the presence of measurable insulin secretion have proven useful in predicting near-normoglycemic remission and long-term insulin dependence in adult patients with a history of diabetic ketoacidosis. This clinical presentation is commonly reported in African and African-American persons but is also observed in Hispanic persons and those from other minority ethnic groups. The underlying mechanisms for β-cell dysfunction in ketosis-prone type 2 diabetes are not known; however, preliminary evidence suggests an increased susceptibility to glucose desensitization.

Figures

Grahic Jump Location
Figure.
Levels of plasma C-peptide before and after glucagon stimulation (1 mg intravenously) in patients with ketosis-prone type 2 diabetes.(2, 3)

Insulin secretion was assessed 1 day after resolution of diabetic ketoacidosis (at presentation) and after 10 weeks of follow-up . Data are expressed as means and SDs. Acute insulin response to glucagon is the incremental change in C-peptide level over the baseline level. To convert values to nmol/L, multiply by 0.333.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)